Penetrium Bioscience Registration Statement Becomes Effective for 15.32% Dilutive Rights Offering of 344 Billion Won
The Financial Supervisory Service notified that the securities registration statement submitted by Penetrium Bioscience on June 11, 2026 became effective on June 26, 2026.
This effectiveness confirms the rights offering of 8.5 million new shares at 4,050 won per share, resulting in an unavoidable 15.32% dilution of existing shares.
Approximately 78% of the raised 344 billion won, or 269 billion won, will be used for clinical development of solid tumors and rheumatoid arthritis, while 20 billion won is allocated to repay loans from Industrial Bank of Korea.
The company has recorded consecutive operating losses and negative operating cash flow over the past three years, and with cash and cash equivalents of only 2.2 billion won at end-Q1 2026, liquidity risk remains high.
The largest shareholder, Hyundai Bioscience, plans to fully participate in its allocation, but 62.53% of its shares are pledged as collateral, posing a margin call risk if the stock price declines.
The company holds 683,321 treasury shares with no plans for additional purchase or cancellation.
Since 2022, the stock has been designated as a cautionary item 10 times, a warning item 5 times, and a risk item once, indicating persistent designation risk.
[AI Summary]This effectiveness notice marks the legal completion of a rights offering that dilutes existing shareholders by 15.32%, negatively impacting shareholder value. The reduced fundraising scale may delay clinical timelines, and while short-term financial structure improves, the success of core pipeline clinical trials remains the key to enterprise value.
KOSDAQ Filing Information
Notice Of Effectiveness (Securities Registration Statement (Equity Securities) Filed On June 11, 2026)